Webcast

FTC Announces Special Open Commission Meeting on Rule to Ban Noncompetes

Retrieved on: 
星期四, 四月 18, 2024
Webcast, Commission, Social media, Policy, Blog, News, Federal Trade Commission, FTC

Today, Federal Trade Commission Chair Lina M. Khan announced that a special Open Commission Meeting will be held virtually on Tuesday, April 23, 2024, at 2pm ET.

Key Points: 
  • Today, Federal Trade Commission Chair Lina M. Khan announced that a special Open Commission Meeting will be held virtually on Tuesday, April 23, 2024, at 2pm ET.
  • The following item will be on the agenda:
    Business Before the Commission:
    Rule to Ban Noncompetes Clauses:
    The Commission will vote on whether to issue a proposed final rule that would prevent most employers from enforcing noncompetes against workers.
  • The proposed final rule the Commission will consider stems from the notice of proposed rulemaking the FTC issued in January 2023, which was subject to a 90-day public comment period.
  • At the start of the meeting, the Commission will vote on whether to authorize public disclosure of the proposed final rule that is under consideration.

FTC Announces Special Open Commission Meeting on Rule to Ban Noncompetes

Retrieved on: 
星期四, 四月 18, 2024
Webcast, Commission, Social media, Policy, Blog, News, Federal Trade Commission, FTC

Today, Federal Trade Commission Chair Lina M. Khan announced that a special Open Commission Meeting will be held virtually on Tuesday, April 23, 2024, at 2pm ET.

Key Points: 
  • Today, Federal Trade Commission Chair Lina M. Khan announced that a special Open Commission Meeting will be held virtually on Tuesday, April 23, 2024, at 2pm ET.
  • The following item will be on the agenda:
    Business Before the Commission:
    Rule to Ban Noncompetes Clauses:
    The Commission will vote on whether to issue a proposed final rule that would prevent most employers from enforcing noncompetes against workers.
  • The proposed final rule the Commission will consider stems from the notice of proposed rulemaking the FTC issued in January 2023, which was subject to a 90-day public comment period.
  • At the start of the meeting, the Commission will vote on whether to authorize public disclosure of the proposed final rule that is under consideration.

EQS-News: HomeToGo Releases 2024 Outlook: Strong Growth in IFRS Revenues of >35% YoY to €>220M Alongside Significant Adjusted EBITDA Growth. Share Tender Offering Announced

Retrieved on: 
星期三, 四月 10, 2024
DACH, Software as a service, Interest, Growth, Q&A, Frankfurt Stock Exchange, Eggo, CFO, Partnership, Webcast, Share repurchase, Acquisition, Introduction, AI, IPO, Record, Adjustment, Yoy, HTG, Annual report, Marketplace, Marketing, Service, Pharmaceutical industry

HomeToGo Releases 2024 Outlook: Strong Growth in IFRS Revenues of >35% YoY to €>220M Alongside Significant Adjusted EBITDA Growth.

Key Points: 
  • HomeToGo Releases 2024 Outlook: Strong Growth in IFRS Revenues of >35% YoY to €>220M Alongside Significant Adjusted EBITDA Growth.
  • HomeToGo Releases 2024 Outlook: Strong Growth in IFRS Revenues of >35% YoY to €>220M Alongside Significant Adjusted EBITDA Growth.
  • Booking Revenues to grow to €>250M (>30% YoY) vs. €190.1M in FY/23
    IFRS Revenues to grow to €>220M (>35% YoY) vs. €162.0M in FY/23
    Adj.
  • EBITDA to grow to €>10M (>400% YoY) vs. €1.8M in FY/23
    Booking Revenues of €190.1M for FY/23 (16% YoY), surpassing FY/23 financial guidance.

EQS-News: CPI PROPERTY GROUP publishes financial results for 2023

Retrieved on: 
星期三, 四月 10, 2024
WAULT, EUR, CPI, Growth, Capital expenditure, ICR, Environment, GSG, Hotel, Webcast, CEE, NAV, EPRA, Investment, LTV, FFO

CPI PROPERTY GROUP (hereinafter “CPIPG”, the “Company” or together with its subsidiaries the “Group”), a leading European landlord, hereby publishes audited financial results for the financial year ended 31 December 2023.

Key Points: 
  • CPI PROPERTY GROUP (hereinafter “CPIPG”, the “Company” or together with its subsidiaries the “Group”), a leading European landlord, hereby publishes audited financial results for the financial year ended 31 December 2023.
  • “CPIPG’s results in 2023 demonstrate the resilient and high-yielding nature of real estate in the CEE region,” said David Greenbaum, CEO.
  • The Group raised over €2.5 billion of secured and unsecured external financing in 2023, including €1.2 billion of fresh cash.
  • CPIPG will host a webcast in relation to its financial results for 2023.

EQS-News: Ekosem-Agrar AG plans to restructure its outstanding corporate bonds

Retrieved on: 
星期三, 四月 10, 2024
EUR, SDK, Joint, ESA, Webcast, FAQ, Sale, Bank statement, Federal Gazette, Gesellschaft mit beschränkter Haftung, Security (finance)

The proposed measures essentially comprise the sale and transfer of the outstanding bonds including accrued interest at a purchase price of EUR 300.00 per bond with a nominal value of EUR 1,000.00.

Key Points: 
  • The proposed measures essentially comprise the sale and transfer of the outstanding bonds including accrued interest at a purchase price of EUR 300.00 per bond with a nominal value of EUR 1,000.00.
  • Furthermore, the management plans to merge the German holding company with the operating business, which is based exclusively in Russia.
  • The current shareholders of Ekosem-Agrar AG will essentially hold the shares in the acquiring company.
  • Our bonds have been an important financial pillar in building up our business since 2012, combined with an attractive return for our noteholders.

EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Retrieved on: 
星期三, 四月 10, 2024
EST, Q&A, Patient, Webcast, Document, Annual report, Euronext Paris, AMF, Therapy, Cryptocurrency

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Key Points: 
  • Abivax publishes financial reports with the French and U.S. securities regulatory agencies
    The issuer is solely responsible for the content of this announcement.
  • The Universal Registration Document includes the 2023 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.
  • To participate and ask questions during the webcast, please register via the Abivax website .

EQS-News: MEDICLIN invites you to the virtual press conference on the financial statements for the year 2023

Retrieved on: 
星期三, 四月 10, 2024
Webcast, Bank statement, Ticker, Q&A, MED, WKN

MEDICLIN (Ticker: MED; WKN 659 510) invites you to the virtual press conference on the financial statements for the year 2023.

Key Points: 
  • MEDICLIN (Ticker: MED; WKN 659 510) invites you to the virtual press conference on the financial statements for the year 2023.
  • The event will take place on
    The Management Board of MEDICLIN will report on the 2023 financial year, current developments at MEDICLIN and the outlook for 2024 in a webcast.
  • To participate in the press conference, please register at the following link:
    You will then receive the link to the webcast and the dial-in details for the telephone connection.
  • The replay of the webcast (without the Q&A session) will be available on the MEDICLIN website soon after the press conference.

EQS-News: Abivax reports 2023 financial results and operational update

Retrieved on: 
星期三, 四月 10, 2024
Q&A, Nomination, New Drug Application, Patient, Shanda, MRO, G&A, IND, EQT, Marketing, Research, EST, McKinsey & Company, Carcinoma, Schering-Plough, Partnership, Webcast, SVP, IBD, Inflammatory Bowel Diseases, American College, Safety, Phase 10, Compensated emancipation, BB Biotech, URD, IPO, F2G, Sofinnova, FDA, AbbVie, EUR, Abstract, Takeda, Pharmaceutical industry

Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.

Key Points: 
  • Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.
  • Cash position (including other financial assets of EUR 9.0M) at the end of 2023 was EUR 261.0M, compared to EUR 27.0M at the end of 2022.
  • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.

EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期三, 四月 10, 2024
Novartis, ASH, Tafasitamab, Webcast, Purchasing, EZH1, EDT, Acquisition, Standard of care, BET, Business analyst, EZH2, Ruxolitinib, Exposition, Society, Safety, Anemia, GMT, MorphoSys, JAK, Annual general meeting, Pharmaceutical industry

“Now, in 2024, we are pleased that Novartis is committing to the future of our promising pipeline.

Key Points: 
  • “Now, in 2024, we are pleased that Novartis is committing to the future of our promising pipeline.
  • With its ample resources, additional scientific expertise and global footprint, Novartis can help accelerate pelabresib's potential worldwide.
  • Total revenues for the fourth quarter 2023 were € 59.0 million compared to € 81.6 million for the same period in 2022.
  • The decrease resulted first and foremost from prior year revenues stemming from the execution of an out-licensing agreement with Novartis.

Exponent to Announce First Quarter of Fiscal Year 2024 Results and Host Quarterly Conference Call on April 25, 2024

Retrieved on: 
星期二, 四月 9, 2024
Webcast, EXPO, Exponentiation

MENLO PARK, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO), today announced that it will report First Quarter of fiscal year 2024 financial results for the period ended March 29, 2024 following the close of the market on Thursday, April 25, 2024.

Key Points: 
  • MENLO PARK, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO), today announced that it will report First Quarter of fiscal year 2024 financial results for the period ended March 29, 2024 following the close of the market on Thursday, April 25, 2024.
  • On that day, Dr. Catherine Corrigan, Chief Executive Officer and President, and Richard Schlenker, Executive Vice President and Chief Financial Officer, will host a conference call and webcast at 4:30 p.m.
  • ET (1:30 p.m. PT) to discuss the Company’s business and financial results.